CAR-T cell therapy
Also written as: CAR-T — Chimeric Antigen Receptor T-cell
Immunotherapy using genetically modified T cells that express chimeric antigen receptors to target cancer cells.
Full Definition
Chimeric Antigen Receptor T-cell therapy represents a breakthrough immunotherapy approach where a patient's T cells are genetically engineered to express synthetic receptors that recognize specific cancer antigens. The therapy involves collecting the patient's T cells, modifying them in a laboratory, expanding the population, and reinfusing them. CAR-T therapy has shown remarkable efficacy in certain B-cell malignancies but carries significant risks including cytokine release syndrome and neurotoxicity. Editorial note: the hyphenation is standardized across medical literature.
Usage
Usage note: Hyphenate CAR-T; do not use CART or Car-T variants
In Context
- "CAR-T cell therapy achieved durable remission in 40% of patients with relapsed B-cell lymphoma." — Clinical research publication
- "The FDA approved tisagenlecleucel as the first CAR-T cell therapy for pediatric acute lymphoblastic leukemia." — Regulatory announcement